Please select the option that best describes you:
How do you choose your next line of therapy for stage 4 GIST after progression on imatinib?
How do you choose between local therapy (surgical debulking or ablation) v. 2nd line systemic therapy? Would you consider immunotherapy?
Answer from: Medical Oncologist at Academic Institution
At Sylvester we have found that patients with GIST whose tumors progress in imatinib often harbor resistance mutations that may be detected by a blood test called “circulating tumor DNA”. There is growing evidence that patients with one type of mutation do much better with sunitinib whil...
Sign in or Register to read more